Your browser doesn't support javascript.
loading
Accelerating the speed of innovative anti-tumor drugs to first-in-human trials incorporating key de-risk strategies.
Wang, Yuqi; Quan, Quan; Gleason, Camille; Yu, Helin; Peng, Lujia; Kang, Yanshen; Jiang, Ling; Wu, Kailun; Pan, Jie; Bao, Moxiyele; Zhu, Qing; Yi, Meiqi; Fang, Ming; Zheng, Yue; Qiu, Ling; Xu, Bin; Li, Xiang; Song, Jinfeng; Sun, Jiamu; Zhang, Zheng; Su, Zijun; Lin, Jara; Xie, Yuanyuan; Xu, April; Song, Xiling; Huang, Chichi; Shen, Zhirong; Wang, Lai; Song, Jing.
Afiliación
  • Wang Y; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Quan Q; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Gleason C; Department of Regulatory Affairs CMC, BeiGene USA, Inc, San Mateo, CA, USA.
  • Yu H; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Peng L; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Kang Y; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Jiang L; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Wu K; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Pan J; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Bao M; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Zhu Q; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Yi M; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Fang M; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Zheng Y; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Qiu L; Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, China.
  • Xu B; Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, China.
  • Li X; Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, China.
  • Song J; Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, China.
  • Sun J; Department of Regulatory Affairs CMC, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Zhang Z; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Su Z; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Lin J; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Xie Y; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Xu A; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Song X; Department of Regulatory Affairs CMC, BeiGene USA, Inc, San Mateo, CA, USA.
  • Huang C; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Shen Z; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Wang L; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
  • Song J; Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China.
MAbs ; 15(1): 2292305, 2023.
Article en En | MEDLINE | ID: mdl-38095560
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos / COVID-19 / Antineoplásicos Límite: Humans Idioma: En Revista: MAbs Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos / COVID-19 / Antineoplásicos Límite: Humans Idioma: En Revista: MAbs Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos